Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Core Insights - Quoin Pharmaceuticals Ltd. has launched the "NETHERTON NOW" campaign to raise awareness about Netherton Syndrome, a genetic disease with a high misdiagnosis rate and a significant mortality rate among affected infants [1][4] - The company is conducting four clinical studies on QRX003, a treatment for Netherton Syndrome, with recent data indicating its potential efficacy [3][8] - The NETHERTON NOW website serves as a resource hub for patients and families, promoting education and advocacy for those affected by the disease [4][6] Company Overview - Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a pipeline that includes products targeting multiple conditions [9] - QRX003 is a topical lotion designed to improve skin barrier function in Netherton Syndrome patients by mimicking the action of a specific protein absent in these patients [8] Clinical Development - The company has received FDA clearance to initiate a "whole body" clinical study for QRX003, marking a significant step in its clinical development [3] - Quoin aims to compile a robust data package to support regulatory approval filings in the US, EU, and 61 other countries [3][4] Patient Impact - Netherton Syndrome leads to severe skin issues, chronic infections, and a high risk of dehydration, significantly affecting patients' quality of life [2][7] - The campaign aims to address the emotional and social challenges faced by patients and their families, emphasizing the need for better understanding and treatment options [4][5]